EMILY FISCHER: Open Payments
NPI 1164199907 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,457 in 68 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $1,353 · 2025 $1,457
Food & beverage: $1,406Education: $51
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $291 |
| GENZYME CORPORATION | 15 | $225 |
| GlaxoSmithKline, LLC. | 13 | $219 |
| Galderma Laboratories, L.P. | 3 | $185 |
| Amgen Inc. | 10 | $167 |
| Novartis Pharmaceuticals Corporation | 7 | $141 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Octapharma USA, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $19 |
Products named: NEMLUVIO, TEZSPIRE, AIRSUPRA, TRELEGY ELLIPTA, DUPIXENT, NEFFY, NUCALA, Rhapsido.
Industry payments across IN — which companies pay providers there.
